Clinical Oncology
Volume 22, Issue 7 , Pages 570-577 , September 2010

Efficacy and Tolerability of Limited Field Radiotherapy with Concurrent Capecitabine in Locally Advanced Pancreatic Cancer

  • A.S.N. Jackson

      Affiliations

    • Academic Radiation Oncology, The University of Manchester, Manchester, UK
    • Corresponding Author InformationAuthor for correspondence: A.S.N. Jackson, Academic Radiation Oncology, Christie Hospital NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK.
    • ,
  • P. Jain

      Affiliations

    • Academic Radiation Oncology, The University of Manchester, Manchester, UK
    • ,
  • G.R. Watkins

      Affiliations

    • Academic Radiation Oncology, The University of Manchester, Manchester, UK
    • ,
  • G.A. Whitfield

      Affiliations

    • Academic Radiation Oncology, The University of Manchester, Manchester, UK
    • ,
  • M.M. Green

      Affiliations

    • Academic Radiation Oncology, The University of Manchester, Manchester, UK
    • ,
  • J. Valle

      Affiliations

    • Department of Medical Oncology, The Christie Hospital NHS Foundation Trust, Manchester, UK
    • ,
  • M.B. Taylor

      Affiliations

    • Department of Radiology, The Christie Hospital NHS Foundation Trust, Manchester, UK
    • ,
  • C. Dickinson

      Affiliations

    • Academic Radiation Oncology, The University of Manchester, Manchester, UK
    • ,
  • P.M. Price

      Affiliations

    • Academic Radiation Oncology, The University of Manchester, Manchester, UK
    • ,
  • A. Saleem

      Affiliations

    • Academic Radiation Oncology, The University of Manchester, Manchester, UK

Received 8 July 2009 ,Revised 22 March 2010 ,Accepted 11 May 2010.

References 

  1. Crane CH, Varadhachary G, Settle SH, Fleming JB, Evans DB, Wolff RA. The integration of chemoradiation in the care of patients with localized pancreatic cancer. Cancer Radiother. 2009;13(2):123–143
  2. Mukherjee S, Hudson E, Reza S, Thomas M, Crosby T, Maughan T. Pancreatic cancer within a UK cancer network with special emphasis on locally advanced non-metastatic pancreatic cancer. Clin Oncol (R Coll Radiol). 2008;20(7):535–540
  3. Radiation therapy combined with adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group. Cancer. 1985;56(11):2563–2568
  4. Moertel CG, Frytak S, Hahn RG, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads+5-fluorouracil), and high dose radiation+5-fluorouracil: the Gastrointestinal Tumor Study Group. Cancer. 1981;48(8):1705–1710
  5. Haddock MG, Swaminathan R, Foster NR, et al. Gemcitabine, cisplatin, and radiotherapy for patients with locally advanced pancreatic adenocarcinoma: results of the North Central Cancer Treatment Group Phase II Study N9942. J Clin Oncol. 2007;25(18):2567–2572
  6. Li CP, Chao Y, Chi KH, et al. Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiat Oncol Biol Phys. 2003;57(1):98–104
  7. Okusaka T, Ito Y, Ueno H, et al. Phase II study of radiotherapy combined with gemcitabine for locally advanced pancreatic cancer. Br J Cancer. 2004;91(4):673–677
  8. Okusaka T, Okada S, Tokuuye K, et al. Lack of effectiveness of radiotherapy combined with cisplatin in patients with locally advanced pancreatic carcinoma. Cancer. 2001;91(7):1384–1389
  9. Park JK, Ryu JK, Lee JK, et al. Gemcitabine chemotherapy versus 5-fluorouracil-based concurrent chemoradiotherapy in locally advanced unresectable pancreatic cancer. Pancreas. 2006;33(4):397–402
  10. Wilkowski R, Thoma M, Bruns C, Wagner A, Heinemann V. Chemoradiotherapy with gemcitabine and continuous 5-FU in patients with primary inoperable pancreatic cancer. JOP. 2006;7(4):349–360
  11. Wilkowski R, Thoma M, Duhmke E, Rau HG, Heinemann V. Concurrent chemoradiotherapy with gemcitabine and cisplatin after incomplete (R1) resection of locally advanced pancreatic carcinoma. Int J Radiat Oncol Biol Phys. 2004;58(3):768–772
  12. Crane CH. In response to Li et al.: Concurrent chemoradiotherapy treatment of locally advanced pancreatic cancer: gemcitabine versus 5-fluorouracil, a randomized controlled study. Int J Radiol Oncol Biol Phys 2003;57:98–104. Int J Radiat Oncol Biol Phys. 2004;58(3):1009;author reply 1009–1010
  13. Crane CH, Janjan NA, Evans DB, et al. Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer. Int J Pancreatol. 2001;29(1):9–18
  14. Sawaki A, Hoki N, Ito S, et al. Clinical impact of radiotherapy for locally advanced pancreatic cancer. J Gastroenterol. 2009;44:1209–1214
  15. Chauffert B, Mornex F, Bonnetain F, et al. Phase III trial comparing intensive induction chemoradiotherapy (60Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO study. Ann Oncol. 2008;19(9):1592–1599
  16. Loehrer PJ, Powell ME, Cardenes HR, et al. A randomized phase III study of gemcitabine in combination with radiation therapy versus gemcitabine alone in patients with localized, unresectable pancreatic cancer: E4201. J Clin Oncol. 2008;26(15S):4506
  17. Passantino L, Patruno R, Valerio P, et al. Thymidine phosphorylase profiles in nonmalignant and malignant pancreatic tissue. Potential therapeutic role of capecitabine on tumoral and endothelial cells and tumor-infiltrating macrophages. Immunopharmacol Immunotoxicol. 2005;27(1):95–107
  18. Van Cutsem E, Peeters M. Oral fluoropyrimidines in colorectal cancer. Semin Oncol. 2000;27(5 Suppl. 10):91–95
  19. Blanquicett C, Saif MW, Buchsbaum DJ, et al. Antitumor efficacy of capecitabine and celecoxib in irradiated and lead-shielded, contralateral human BxPC-3 pancreatic cancer xenografts: clinical implications of abscopal effects. Clin Cancer Res. 2005;11(24 Pt 1):8773–8781
  20. Das P, Wolff RA, Abbruzzese JL, et al. Concurrent capecitabine and upper abdominal radiation therapy is well tolerated. Radiat Oncol. 2006;1:41
  21. Kim HS, Yi SY, Jun HJ, et al. Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer. Anticancer Drugs. 2009;21:17–112
  22. Schneider BJ, Ben-Josef E, McGinn CJ, et al. Capecitabine and radiation therapy preceded and followed by combination chemotherapy in advanced pancreatic cancer. Int J Radiat Oncol Biol Phys. 2005;63(5):1325–1330
  23. Vaishampayan UN, Ben-Josef E, Philip PA, et al. A single-institution experience with concurrent capecitabine and radiation therapy in gastrointestinal malignancies. Int J Radiat Oncol Biol Phys. 2002;53(3):675–679
  24. Kawakami H, Uno T, Isobe K, et al. Toxicities and effects of involved-field irradiation with concurrent cisplatin for unresectable carcinoma of the pancreas. Int J Radiat Oncol Biol Phys. 2005;62(5):1357–1362
  25. McGinn CJ, Zalupski MM, Shureiqi I, et al. Phase I trial of radiation dose escalation with concurrent weekly full-dose gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2001;19(22):4202–4208
  26. Muler JH, McGinn CJ, Normolle D, et al. Phase I trial using a time-to-event continual reassessment strategy for dose escalation of cisplatin combined with gemcitabine and radiation therapy in pancreatic cancer. J Clin Oncol. 2004;22(2):238–243
  27. Tokuuye K, Sumi M, Kagami Y, et al. Small-field radiotherapy in combination with concomitant chemotherapy for locally advanced pancreatic carcinoma. Radiother Oncol. 2003;67(3):327–330
  28. Yamazaki H, Nishiyama K, Koizumi M, et al. Concurrent chemoradiotherapy for advanced pancreatic cancer: 1,000mg/m2 gemcitabine can be administered using limited-field radiotherapy. Strahlenther Onkol. 2007;183(6):301–306
  29. Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group. J Natl Cancer Inst. 1988;80(10):751–755
  30. Klaassen DJ, MacIntyre JM, Catton GE, Engstrom PF, Moertel CG. Treatment of locally unresectable cancer of the stomach and pancreas: a randomized comparison of 5-fluorouracil alone with radiation plus concurrent and maintenance 5-fluorouracil — an Eastern Cooperative Oncology Group study. J Clin Oncol. 1985;3(3):373–378
  31. Saif MW, Eloubeidi MA, Russo S, et al. Phase I study of capecitabine with concomitant radiotherapy for patients with locally advanced pancreatic cancer: expression analysis of genes related to outcome. J Clin Oncol. 2005;23(34):8679–8687
  32. Shinchi H, Takao S, Noma H, et al. Length and quality of survival after external-beam radiotherapy with concurrent continuous 5-fluorouracil infusion for locally unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys. 2002;53(1):146–150
  33. Wilkowski R, Thoma M, Schauer R, Wagner A, Heinemann V. Effect of chemoradiotherapy with gemcitabine and cisplatin on locoregional control in patients with primary inoperable pancreatic cancer. World J Surg. 2004;28(10):1011–1018
  34. Berlin JD, Adak S, Vaughn DJ, et al. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). Oncology. 2000;58(3):215–218
  35. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JA. A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer. 2002;87(2):161–167
  36. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol. 2005;23(15):3509–3516
  37. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol. 2004;22(18):3776–3783
  38. Ceha HM, van Tienhoven G, Gouma DJ, et al. Feasibility and efficacy of high dose conformal radiotherapy for patients with locally advanced pancreatic carcinoma. Cancer. 2000;89(11):2222–2229
  39. Ben-Josef E, Shields AF, Vaishampayan U, et al. Intensity-modulated radiotherapy (IMRT) and concurrent capecitabine for pancreatic cancer. Int J Radiat Oncol Biol Phys. 2004;59(2):454–459
  40. Saif MW, Moody JS, Russo SM. Gastrointestinal bleeding associated with concurrent capecitabine and radiotherapy in patients with pancreatic cancer. JOP. 2005;6(4):325–333
  41. Milano MT, Chmura SJ, Garofalo MC, et al. Intensity-modulated radiotherapy in treatment of pancreatic and bile duct malignancies: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys. 2004;59(2):445–453
  42. Crane CH, Ellis LM, Abbruzzese JL, et al. Phase I trial evaluating the safety of bevacizumab with concurrent radiotherapy and capecitabine in locally advanced pancreatic cancer. J Clin Oncol. 2006;24(7):1145–1151
  43. Feng M, Balter JM, Normolle D, et al. Characterization of pancreatic tumor motion using cine MRI: surrogates for tumor position should be used with caution. Int J Radiat Oncol Biol Phys. 2009;74(3):884–891
  44. Crane CH, Antolak JA, Rosen , et al. Phase I study of concomitant gemcitabine and IMRT for patients with unresectable adenocarcinoma of the pancreatic head. Int J Gastrointest Cancer. 2001;30(3):123–132
  45. Landry JC, Yang GY, Ting JY, et al. Treatment of pancreatic cancer tumors with intensity-modulated radiation therapy (IMRT) using the volume at risk approach (VARA): employing dose-volume histogram (DVH) and normal tissue complication probability (NTCP) to evaluate small bowel toxicity. Med Dosim. 2002;27(2):121–129

PII: S0936-6555(10)00204-9

doi: 10.1016/j.clon.2010.06.007

Clinical Oncology
Volume 22, Issue 7 , Pages 570-577 , September 2010

Article Tools

* Image Usage & Resolution